Pharmaceutical Executive-02-01-2016

Pharmaceutical Executive

Life and Lipitor: Pfizer's Traci Medford-Rosow

February 09, 2016

Columns

36

2

In the patent scrum, a litigator finds her true self.

The Staying Power of Emerging Markets

February 08, 2016

Features

36

2

Whatever used to be wrong with the world of big Pharma could be fixed with a single tag phrase: emerging country markets. Most of the majors have invested heavily in this geographic segment, and the biggest of the big-companies like Novartis-now rely on it for more than a quarter of their global sales. Like all good things, however, there are shadows amidst the sunlight, and the task of turning volume sales into sustainable profits is getting harder.

Canada's Rx&D: Fresh Start for a New Era

February 05, 2016

Columns

36

2

Canada’s Rx&D, the industry’s oldest functioning trade association, recently changed its name-with a mission of bridging the many points of collaboration that drive the process of modern drugs, from discovery to market.

Morgan Moments: A Closer Reading of the JP Morgan Investor Conference

February 05, 2016

From the Editor

36

2

A closer reading of this year's JP Morgan investor conference identifies three areas where the insular, often maladroit tone of the industry-investor dialogue may be morphing to something more grounded in the larger societal context of healthcare.

Securing Cipla’s Future

February 01, 2016

Features

36

2

Pharm Exec interviews Subhanu Saxena, CEO of India pharma giant Cipla, who discusses the longtime emerging market champion’s strategic plans to raise its geographic profile and secure the company’s future in the US.

Country Report: South Africa

February 01, 2016

Special Sponsored Section

36

2

In tandem with South Africa’s institutional advancements, driven by sweeping social and macroeconomic reforms, the pharma industry in the region is capitalizing on its core fundamentals: rising consumer disposable income, a positive demographic profile linked to an aging population, and a diverse disease burden requiring novel cures and treatments.

Pharmaceutical Executive, February 2016 Issue (PDF)

February 01, 2016

Issue PDF

36

2

Click the title above to open the Pharmaceutical Executive February 2016 issue in an interactive PDF format.